ライフサイエンスコーパス: postdose

1 e plasma isotopic-ratio measurement (18-25 d postdose).

2 t had been converted to 5-MTHF after 15 min (postdose).

3 level of inhibition remaining at 40% at 12 h postdose.

4 uld provide protection for at least 24 hours postdose.

5 als containing 1-6 g gluten at 20-65 minutes postdose.

6 nths was 34.9% predose and 55.7% at 2 hours' postdose.

7 ection) were also evaluated through 150 days postdose.

8 eding assays predose and at 1, 4, and 7 days postdose.

9 echoDoppler cardiography predose and 2-hours postdose.

10 hs 1 and 5 using blood samples drawn 2 hours postdose.

11 n KMS-12-BM multiple myeloma tumors for 16 h postdose.

12 edom from the most bothersome symptom at 2 h postdose.

13 antly reduced blood glucose levels up to 6 h postdose.

14 antified in individual brain sections 45 min postdose.

15 Elevation of IGF-1 levels was observed postdose.

16 istration, with peak concentrations 1-6 days postdose.

17 therapies or colectomy during the first year postdose.

18 olic equivalents [METS], Bruce protocol) 1 h postdose.

19 f (2)H(2)- and (13)C(5)-labeled folates 48 h postdose.

20 d until the effect was fully reversed by 3 h postdose.

21 test at 12 weeks, but in decline by 24 weeks postdosing.

22 immunogenicity were assessed through 1-year postdosing.

23 patients who were HCV RNA-negative 76 weeks postdosing.

24 ry relative to maternal serum enrichment 2 h postdosing.

25 days 1 (4, 8, and 12 hours), 2, 4, 7, and 14 postdosing.

26 2,000-fold over the IC(90) value for 7 days postdosing.

27 ses and were generally undetectable by 24-hr postdosing.

28 ta and correlated with serum D:H at 3 or 6 d postdosing.

29 inol equilibrated with the body pool by 20 d postdosing.

30 in previously GBS-vaccinated women exceeded postdose 1 GMCs in previously non-GBS-vaccinated women (

31 each serotype 60 days postdose 2 vs 36%-56% postdose 1 in previously non-GBS-vaccinated women.

32 lent GBS vaccine dose administered 4-6 years postdose 1 was immunogenic with a favorable safety profi

33 t) was sustained in >=90% of women at 1 year postdose 1.

34 administered to nonpregnant women 4-6 years postdose 1.

35 nitoring (approximately 16 h predose to 24 h postdose); 12-lead electrocardiograms (ECGs); clinical c

36 healthy male subjects underwent baseline and postdose (18)F-JNJ-64413739 PET/MRI scans 4-6 h after th

37 with undetectable baseline anti-GBS levels, postdose 2 GMCs in previously GBS-vaccinated women excee

38 metric mean concentrations (GMCs) 30/60 days postdose 2 in previously GBS-vaccinated women were >=200

39 hreshold (8 ug/mL) for each serotype 60 days postdose 2 vs 36%-56% postdose 1 in previously non-GBS-v

40 i-GBS levels, 90%-98% reached this threshold postdose 2.

41 y (D) 43, and D91 for GBS serotypes; 1 month postdose 3 (D127) for diphtheria; and 1 month postprimar

42 ometric mean concentrations from baseline to postdose 3 showed significant increases in antibody leve

43 ths, significant increases from predose 4 to postdose 4 (GMFR range, 3.00-6.97), and little change af

44 rected near visual acuity (DCNVA) at 3 hours postdose after >=14 days of treatment.

45 dian peak plasma concentrations at 1-2 hours postdose and mean terminal half-life of 12-15 hours.

46 rdiography were monitored predose to 5 hours postdose and transthoracic echoDoppler cardiography pred

47 In all trials, urine was collected 24-36 h postdosing and the isotopic labeling of urinary folates

48 were temporally similar with respect to time postdose (and the postdose timing of an NSVT event in a

49 g algorithm to distinguish between controls, postdose, and predose samples.

50 in UPDRS motor score from predose to 30 min postdose, assessed at week 12 during an in-clinic off pe

51 ian hemoglobin change from baseline to first postdose assessment was -0.7 g/dL (range, -3.1 to +2.4).

52 ian hemoglobin change from baseline to first postdose assessment was -0.9 g/dL (range, -3.6 to 2.5 g/

53 timeline for vitamin B-12 administration and postdose assessment.

54 prespecified analyses that include pre- and postdose assessments at 4 and 12 weeks, treatment with s

55 SB1518 inhibited JAK2 signaling at 4 hours postdose at all levels.

56 formed at baseline and at trough and 4 hours postdose at weeks 4 and 12.

57 lated to dose, plasma concentration, or time postdose at which samples were obtained, but was positiv

58 e from time of administration up to 24 hours postdosing at day 7: 35 840, 34 980, and 39 627 ng x hou

59 the next dose of tiotropium), peak, and 6-h postdose average FEV(1) and FVC, and in PEFR, without a

60 Twenty minutes postdose, beta-glucocerebrosidase activity increased ove

61 1.05 ng/mL (range, 2.84-147.1 ng/mL) 2 hours postdose but was below assay sensitivity 6 hours after d

62 i-spike and 36 (55%) for anti-RBD by 28 days postdose, but a robust response, defined by reaching the

63 roemulsion (CsA-ME; Neoral) exposure 2 hours postdose (C2) has been reported to optimize the efficacy

64 , SP, CVF and rectal tissue (RT) at 24 hours postdose (C24h) on day 28 and week 12 using a validated

65 e curve (AUC), and concentration at 24 hours postdose (C24h) were 0.91 (90% confidence interval [CI],

66 otein-unbound BIC concentrations at 24 hours postdose (C24h) were quantified in BP, SP, CVF and recta

67 During the first 24 h postdose, cases excreted less (f1.gif" BORDER="0"> +/- S

68 Linezolid trough, 2-hour, and 6-hour postdose clinical samples from across North America were

69 under the curve (AUC), maximum concentration postdose (Cmax), minimum concentration postdose (Cmin),

70 ation postdose (Cmax), minimum concentration postdose (Cmin), time to maximum concentration (Tmax).

71 c study, minimum Concentration (Cmin), 12-hr postdose concentration (Clast), and average concentratio

72 e-response analysis suggested that a 24-hour postdose concentration of KAF156 of 21.5 ng/mL (90% conf

73 Targeting 2-hr postdose cyclosporine (C2) levels to 1,000 to 1,700 mg/d

74 nstrument was administered predose and daily postdose Days 1-6.

75 hepatic CDK1 content by 1.9-6.3-fold through postdosing days 1-5.

76 Postdosing dual-isotope single photon emission computed

77 ma samples were collected at 6, 12, and 24 h postdose during the first day and at 15 time points duri

78 collected throughout pregnancy, and pre- and postdose electrocardiograms were recorded at 20, 28, and

79 s were a postdose SCr increase > or = 25%, a postdose estimated glomerular filtration rate decrease o

80 A significantly greater increase in 2-hour postdose FEV(1) at the endpoint was observed after treat

81 The postdose fibrinogen range was 1.2 to 3.3 g/L (72% within

82 case consisted of a predosing baseline and a postdosing follow-up MRI of patients from aducanumab cli

83 lergen challenge was performed on day 6 (2 h postdose), followed by methacholine challenge (day 7), a

84 ood was collected 14 (D14) and 84 (D84) days postdosing for the assessment of Fe status indicators an

85 ssayed at baseline and at 1, 4, and 24 hours postdose in cycle 1.

86 adduct was also identified in 96 h and 168 h postdose in vivo cynomolgus monkey plasma.

87 ncrease in serum lactate from 24 to 72 hours postdosing in the treated subjects alone (P< 0.005).

88 ges in RBC Fe isotope enrichment for 84 days postdosing in toddlers at high risk for parasitic infect

89 m time zero to the concentration at 24 hours postdose) increased 2- to 3-fold with repeated dosing in

90 pirin on repeated exposure, extension of the postdosing interval, or addition of aspirin to their pla

91 e were assessed before dosing and at various postdose intervals.

92 The proportion of patients with any single postdose intraocular pressure >/=30 mmHg was 9.2%, 6.6%,

93 At postdose liver biopsy, fazirsiran reduced median liver Z

94 One hour postdose liver, adipose, and brain tissue 11beta-HSD1 in

95 ibition than clopidogrel (e.g., 4 weeks, 4-h postdose [mean (+/-SD)]: clopidogrel 64% [+/-22%], AZD61

96 based on erythrocyte (57)Fe enrichment 2 wk postdosing measured using magnetic sector thermal ioniza

97 Serum D:H 3 d postdosing might be used as an early indicator of total

98 However, adverse events, postdose nausea with high-dose azithromycin, effectivene

99 e no differences between treatment arms with postdose nausea, vomiting, or other adverse events.

100 interleukin-6 levels were detected 1 to 6 hr postdosing only at the three highest doses and were gene

101 5)]PteGlu(1) excreted during the second 24 h postdose or when the data were averaged over 48 h.

102 Postdose PC(20)FEV(1) results met standard bioassay stud

103 by 1.88-fold compared to baseline during the postdosing period (95% CI, 1.03- to 3.43-fold; P = .04).

104 d to nondeuterated retinol (D:H) at 3 or 6 d postdosing predicted body stores, and 3) the ability of

105 n increased risk of QTc prolongation and the postdose QTc intervals progressively decreased.

106 stimates of body stores and serum D:H at 3 d postdosing (r = -0.75, P = 0.002); at 6 d postdosing, th

107 bitril-valsartan was associated with greater postdose reductions in aortic Z(c).

108 Postdose reductions in Z(c) were greater in the sacubitr

109 With LVEF<0.40, postdose reductions in Z(c) were greater in the sacubitr

110 565 +/- 149 minutes and 581 +/- 150 minutes postdose, respectively.

111 At 2 h postdose, rimegepant orally disintegrating tablet was su

112 Predose and postdose safety assessments included orthostatic vital s

113 subset of individuals (n = 6) with immediate postdose sampling (HIV-1 RNA increase, 2.96-fold; 95% CI

114 ice or three times a day, the 11- to 13-hour postdose sampling time, and the moderate doses given.

115 elation to daily clozapine dosing schedules, postdose sampling time, and total daily dose, may help t

116 The primary outcome was a postdose SCr increase > or = 0.5 mg/dL (44.2 micromol/L)

117 Secondary outcomes were a postdose SCr increase > or = 25%, a postdose estimated g

118 One- and 7-h postdose sections of the ileum, proximal- and distal-col

119 ach dose), 24-h urine TMAO, predose and 24-h postdose serum hsCRP, and plasma oxidized LDL were measu

120 A shorter time to the first postdose spontaneous bowel movement and a higher mean nu

121 o laxatives before enrollment, time to first postdose spontaneous bowel movement, and mean number of

122 Few children reported postdosing symptoms, with no differences in the frequenc

123 trolled vitamin A dosing trial with pre- and postdose testing of dark-adaptation threshold.

124 At 3 days postdosing, TFV-DP concentrations in peripheral blood mo

125 d postdosing (r = -0.75, P = 0.002); at 6 d postdosing, the correlation was weaker.

126 At one year postdosing, the DGT-uptake fluxes were converging toward

127 tarting from 5 days before chemotherapy (pre/postdoses, three/one or one/one) compared with only four

128 milar with respect to time postdose (and the postdose timing of an NSVT event in a monkey).

129 Both the pre- and postdosing tissue samples adjacent to tumors show no def

130 test of cure, serum gentamicin concentration postdose to establish peak concentration (Cmax), and sta

131 tment visit provided data from 8 to 12 hours postdose, to examine maintenance of effect.

132 During the first 8 h postdosing, triglyceride-rich lipoproteins (TRLs) were p

133 patients given rhTPO by other schedules (pre/postdoses, two/two, one/three, zero/four, or four/zero)

134 sing a Lassen plot and regional baseline and postdose V(T) Results: The average (mean +/- SD) effecti

135 RS motor score change from predose to 30 min postdose was -5.91 (SE 1.50, 95% CI -8.86 to -2.96) for

136 Iron incorporation into red blood cells 14 d postdosing was similar (6.9 +/- 4.2% compared with 7.9 +

137 Serum samples at days 150, 365, and 545 postdose were assayed for ADA titers.

138 er samples taken from the microcosms at 24 h postdosing were used in acute toxicity tests with two st

139 egation in response to ADP between 2 and 8 h postdose with the level of inhibition remaining at 40% a

140 Antibody levels peaked 1 hour postdosing with Active film (median: 35 ug/mL) and remai

141 re measured in maternal blood collected 2 wk postdosing with oral (57Fe) and intravenous (58Fe) stabl